← All trials
NCT07118696
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 1, 2026
- Primary completion
- Jan 31, 2029
- Completion date
- Jan 31, 2030
- First posted
- Aug 12, 2025
- Last posted
- Aug 12, 2025
- Enrollment
- 1000
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Hamilton Health Sciences CorporationLead sponsor
- University of LondonOfficial
- University of LondonCollaborator
- McMaster UniversityCollaborator
- McMaster UniversityOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.